About
SenzaGen develops and provides in vitro genomic-based assays, including its GARD technology, to predict chemical and cosmetic allergy and immunotoxicity, offering non-animal testing solutions for skin sensitization and toxicity testing.
Explore SenzaGen's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.